StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Hold

ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research analysts have also recently issued reports on ANIP. Guggenheim lifted their target price on ANI Pharmaceuticals from $55.00 to $59.00 in a research report on Tuesday, May 9th. HC Wainwright lifted their target price on ANI Pharmaceuticals from $53.00 to $60.00 in a research report on Tuesday, May 9th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $55.67.

ANI Pharmaceuticals Trading Down 0.9 %

Shares of ANI Pharmaceuticals stock opened at $45.97 on Friday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.08 and a current ratio of 2.90. ANI Pharmaceuticals has a 52 week low of $22.31 and a 52 week high of $52.23. The stock has a 50 day moving average price of $39.75 and a two-hundred day moving average price of $40.68. The stock has a market capitalization of $826.08 million, a PE ratio of -26.88 and a beta of 1.04.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) last announced its quarterly earnings data on Thursday, March 9th. The specialty pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.10. ANI Pharmaceuticals had a positive return on equity of 10.60% and a negative net margin of 7.34%. The firm had revenue of $94.23 million during the quarter, compared to analysts’ expectations of $86.76 million. As a group, equities analysts anticipate that ANI Pharmaceuticals will post 2.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in ANI Pharmaceuticals by 9.9% in the first quarter. BlackRock Inc. now owns 1,853,463 shares of the specialty pharmaceutical company’s stock worth $52,103,000 after purchasing an additional 166,850 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 775,299 shares of the specialty pharmaceutical company’s stock valued at $21,793,000 after buying an additional 58,523 shares during the last quarter. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 72.3% during the 1st quarter. Rubric Capital Management LP now owns 648,041 shares of the specialty pharmaceutical company’s stock valued at $25,740,000 after buying an additional 271,909 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,192 shares of the specialty pharmaceutical company’s stock valued at $21,099,000 after buying an additional 4,116 shares during the last quarter. Finally, William Blair Investment Management LLC lifted its position in shares of ANI Pharmaceuticals by 0.3% during the 1st quarter. William Blair Investment Management LLC now owns 529,130 shares of the specialty pharmaceutical company’s stock valued at $21,017,000 after buying an additional 1,665 shares during the last quarter. Hedge funds and other institutional investors own 67.89% of the company’s stock.

About ANI Pharmaceuticals

(Get Rating)

ANI Pharmaceuticals, Inc is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.